Neuberger Berman Group
MNPR icon

Neuberger Berman Group’s Monopar Therapeutics MNPR Stock Holding History

Neuberger Berman Group’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.32M Buy
42,434
+9,887
+30% +$597K ﹤0.01% 1144
2025
Q4 		$2.13M Buy
+32,547
New +$2.66M ﹤0.01% 1159

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Neuberger Berman Group's MNPR Position: Q1 2026 in Review

Neuberger Berman Group increased its Monopar Therapeutics (MNPR) stake by 30% in Q1 2026, buying an estimated $597K and bringing the position to 42,434 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1144.

Neuberger Berman Group first reported a position in MNPR in Q4 2025 and has held it in 2 quarters since. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Neuberger Berman Group held 42,434 shares of Monopar Therapeutics worth $2.32M as of Q1 2026.
  • Neuberger Berman Group bought 9,887 Monopar Therapeutics shares in Q1 2026, an estimated $597K.
  • Monopar Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #1144 holding.
  • Neuberger Berman Group first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.